Technology in Cancer Research & Treatment最新文献

{"title":"Corrigendum to \"A Review on the Application and Mechanism of Low Temperature Plasma in the Field of Tumor Therapy\".","authors":"","doi":"10.1177/15330338261451114","DOIUrl":"10.1177/15330338261451114","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261451114"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13172690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147875782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of RC48-ADC in Combination with PRaG Regimen: An Open-Label, Prospective, Multicentre Study Assessing Efficacy and Safety for Advanced Refractory HER2-Expressing Solid Tumors (PRaG3.0 Study Protocol).","authors":"Meiling Xu, Yuehong Kong, Junjun Zhang, Rongzheng Chen, Pengfei Xing, Xiangrong Zhao, Shicheng Li, Yingying Xu, Liyuan Zhang, Li Zou","doi":"10.1177/15330338261432537","DOIUrl":"10.1177/15330338261432537","url":null,"abstract":"<p><p>IntroductionThis study aims to investigate the effectiveness and safety of combining the antibody-drug conjugate (ADC) disitamab vedotin (RC48) with the established PRaG regimen (PD-1 inhibitor, Radiotherapy, and GM-CSF) for treating HER2-expressing (IHC 3+, 2+, or 1+) advanced solid tumors. This novel PRaG3.0 regimen is hypothesized to leverage the tumor radiosensitizing and immunogenic cell death properties of ADCs to amplify the synergistic antitumor effects of radioimmunotherapy, offering a potential paradigm for pan-cancer therapy.MethodsThis study is a prospective, single-arm, open-label, multi-center clinical trial. Patients enrolled have confirmed HER2-expressing solid tumors (IHC 3+, 2+, or 1+) that have progressed after standard treatment or were intolerant to it. Patients received RC48 (2 mg/kg) via intravenous injection on day 1, followed by subcutaneous GM-CSF at 200 µg from days 3 to 7 and interleukin-2 (IL-2) at 2 million IU from days 8 to 12. Radiotherapy was initiated on day 3, targeting one lesion with hypofractionated radiotherapy (2-3 fractions of 5 or 8 Gy). PD-1/PD-L1 antibodies were administered within one week after completing radiotherapy. Treatment was repeated every three weeks, and if there were no target lesions, radiotherapy could be discontinued, with RC48 given for at least six cycles. After achieving a complete tumor response, maintenance therapy with PD-1/PD-L1 antibodies continued until disease progression or intolerable toxicity occurred. The primary endpoint was the objective response rate (ORR).ResultsThe study is currently in the recruitment phase (Registration No: NCT05115500). The primary endpoint is the objective response rate (ORR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), safety, and QoL. Planned enrollment is 62 patients.ConclusionThe PRaG3.0 protocol represents an innovative approach combining ADC therapy with radioimmunotherapy to address HER2-expressing cancers, including those with HER2-low expression. If successful, this regimen could establish a highly effective combination strategy.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261432537"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12988272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147443923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Adjustable Tandem and Ring Applicator for Improved Dosimetry in Cervical Cancer HDR Brachytherapy.","authors":"Ivan M Buzurovic, Robert A Cormack","doi":"10.1177/15330338261463597","DOIUrl":"10.1177/15330338261463597","url":null,"abstract":"<p><p>IntroductionCervical cancer brachytherapy requires highly conformal dose delivery while minimizing radiation exposure to surrounding organs at risk. However, conventional tandem and ring applicators are limited by fixed geometry that may not optimally accommodate patient-specific anatomy. The purpose of this work was to evaluate the dosimetric performance of a novel tandem and ring applicator (RTA) featuring adjustable tandem translation relative to the ring, intended to improve organ-at-risk (OAR) sparing while preserving target coverage in high-dose-rate (HDR) brachytherapy for cervical cancer.Methods and MaterialsA novel RTA allowing linear tandem translation within the ring plane was developed to enable patient-specific alignment without altering ring position. Two cervical cancer patients treated with external beam radiotherapy (45Gy/25 fractions) followed by HDR brachytherapy (27.5Gy/5 fractions) were analyzed. Conventional and novel RTAs were sequentially applied to acquire CT-based datasets. Plans were optimized for adequate HR-CTV D90 coverage while minimizing D2cm³ doses to bladder, rectum, sigmoid, and bowel. EQD2 values (α/β = 3 for OARs; 10 for HR-CTV) were compared. Five retrospective cases were replanned using the novel RTA. Point A was redefined as 2cm superior along the tandem from the cervical os and 2cm lateral perpendicular to the tandem axis.ResultsFor patient 1, the novel RTA reduced average daily D2cm³ by 0.54Gy (rectum), 0.78Gy (bladder), and 0.18Gy (sigmoid), with cumulative EQD2 reductions of 2.23Gy, 4.88Gy, and 1.05Gy, respectively. Patient 2 showed daily reductions of 0.52Gy (rectum) and 0.44Gy (bladder), with EQD2 decreases of 3.20Gy and 4.55Gy. HR-CTV EQD2 increased by 1.67Gy. Retrospective plans demonstrated consistent reductions in OAR doses.ConclusionThe novel RTA demonstrated favorable dosimetric trends for OAR sparing while maintaining target coverage in cervical HDR brachytherapy. The revised Point A definition provides a preliminary framework for anatomically consistent dose reporting in flexible tandem configurations.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261463597"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148303021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study.","authors":"Xinyue Li, Kaibo Ding, Dujiang Liu, Ruiqi Song, Zhongsheng Peng, Yanjun Xu, Yi Lu","doi":"10.1177/15330338261456203","DOIUrl":"10.1177/15330338261456203","url":null,"abstract":"<p><p>BackgroundThird-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become the first-line treatment for non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations. The optimal treatment strategy after resistance to third-generation EGFR-TKIs still needs further exploration.MethodsThis retrospective study included patients with advanced lung adenocarcinoma who were consecutively enrolled at our hospital between January 2018 and July 2023. All patient data were fully de-identified prior to analysis, and no information that could directly or indirectly identify individual participants was included in this study. We evaluated the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) across various treatment strategies. We also explored the tumor microenvironment (TME) in a subset of patients.ResultsA total of 206 patients were included. Chemo-antiangiogenesis (47.6%) achieved longer mPFS than chemo-immunotherapy (8.00 vs. 5.70 months, p=0.033), with higher ORR (34.7% vs. 16.7%, p=0.003). Median OS was shorter in the immunotherapy group (25.83 vs. 32.33 months, p=0.012). TME analysis (n=27) revealed an immunosuppressive profile (low PD-L1, CCL5, CD8, granzyme B; high Foxp3). In EGFR exon 21 L858R patients, EGFR-TKI continuation was inferior to chemotherapy (mPFS: 3.53 vs. 8.00 months, p=0.001; ORR: 10.5% vs. 40.3%, p=0.015; DCR: 27.4% vs. 69.2%, p=0.009). In oligoprogressive disease, EGFR-TKIs plus radiotherapy improved OS (37.23 vs. 27.77 vs. 25.83 months, p=0.045). Platelet count, LDH, D-dimer, and smoking history were independent predictors of poor prognosis.ConclusionsChemo-antiangiogenesis remains a key treatment option after resistance. For oligoprogressive disease, continuing EGFR-TKIs with local radiotherapy may provide superior survival benefit. Chemo-immunotherapy appears less effective, potentially due to an immunosuppressive TME. Prospective validation is warranted.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261456203"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13219889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148035329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Stimulated Raman Histology as a Novel Method for Pathologic Examination of Urothelial Carcinoma With Unprocessed, Fresh Bladder Cancer Tissue.","authors":"Philipp Maisch, Michael Mühlberger, Annika Beck, Wilhelm Schreen, Miles P Mannas, Cornelia Horsch, Christian Bolenz","doi":"10.1177/15330338261464295","DOIUrl":"10.1177/15330338261464295","url":null,"abstract":"<p><p>IntroductionStimulated Raman histology (SRH) is a recent microscopic technique allowing real-time, label free, high-resolution microscopic images of unprocessed, unsectioned tissue. Tissue samples are imaged in the operating room using a mobile SRH microscope, visualizing histology within minutes.MethodsAim of this prospective first in human feasibility study was to evaluate the use of SRH to identify bladder cancer (BCa) and to test whether a histopathological grading between low- and high-grade tumors can be determined. Therefore, patients with suspicion of BCa, who underwent transurethral resection of bladder tumor were included. Suspicious papillary tissue was resected and subsequently scanned with an SRH microscope (NIO, Invenio Imaging Inc.). After a 10-sample training set, pathologists were tested on a 30-sample test set. Images which were initially classified wrong were re-evaluated within a consensus conference.ResultsThe scanning time was less than 180 seconds for all tissues samples. Individual pathologists' overall combined accuracy (CA) for interpretation of low and high grade SRH images was 76.5 % [95% confidence interval (CI): 65.8-85.3]. After the consensus conference pathologists' overall CA for interpretation of low and high grade SRH images was 96.3 % [95% CI: 89.6-99.2], respectively. The sensitivity for the identification of high-grade tumors was between 66.0 % and 66.7 % before the consensus conference, increasing to 100 % after pathologic consensus. The specificity of the three pathologists was between 83.3 % and 100 %. After the consensus conference, the specificity was on average 91.7 %.ConclusionAfter further investigations, including the testing against benign tissue, SRH might be a reliable point of care-technique to produce high-resolution images of unprocessed bladder tumors, allowing histopathological identification of BCa. Low- and high-grade tumors can be accurately discriminated.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261464295"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148707615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robustness and Accuracy of Radiomics Models for Classifying IASLC Grading in Lung Adenocarcinomas: A Comprehensive Analysis of a Large Multicenter CT Database.","authors":"Xiaohong Fan, Jinqiu Deng, Yujie Feng, Wanyin Qi, Shanyue Lin, Ying Zeng, Zhichao Zuo","doi":"10.1177/15330338261429796","DOIUrl":"10.1177/15330338261429796","url":null,"abstract":"<p><p>IntroductionAccurate preoperative prediction of the International Association for the Study of Lung Cancer (IASLC) grading is crucial for developing individualized management and surgical strategies in lung adenocarcinomas (LUAD). Computed tomography (CT) radiomics serves as an important imaging biomarker for classification tasks in LUAD. However, the robustness and accuracy of radiomics models remain subjects of ongoing debate.MethodsIn this study, we conducted an analytical comparison of two critical steps in radiomics: dimensionality reduction and feature selection, aiming to differentiate between Grade 1 and Grade 2-3 tumors according to the preoperative IASLC grading system for LUAD. 1) For dimensionality reduction, we sequentially combined the T-test, Pearson correlation, and Least Absolute Shrinkage and Selection Operator (LASSO), while considering principal component analysis (PCA) for comparison. 2) For feature selection, we utilized various machine learning (ML) techniques including Logistic Regression (LR), Random Forest (RF), Gradient Boosting (GBC), XGBoost, Light Gradient Boosting Machine (LGBM), and Categorical Boosting (CatBoost). The diagnostic efficacy was evaluated using receiver operating characteristic curve (ROC) and the corresponding area under the curve (AUC).<b>Result:</b> The AUC for PCA combined with various ML feature selection methods ranged from 0.502 to 0.719 in this classification task. In contrast, the AUC for the combined T-test, Pearson, and LASSO dimensionality reduction methods, along with various ML feature selection methods, significantly increased from 0.818 to 0.869. Among these, the LGBM achieved the highest performance, reaching an AUC of 0.869, while LR displayed the lowest performance with an AUC of 0.818.ConclusionWe demonstrated that the T-test→Pearson→LASSO approach is more appropriate for radiomics feature dimensionality reduction compared to PCA. Additionally, we improved the commonly used LR feature selection method in medical research by employing the more advanced LGBM for distinguishing between Grade 1 and Grade 2-3 tumors in accordance with the preoperative IASLC grading system for LUAD.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261429796"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12954028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147318245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-Omic Analysis of Glioma Identifies RRM2 as a Prognostic Biomarker Associated With Tumor Stemness and Cell Cycle-Related Pathways.","authors":"Jiayuan Li, Liubing Hou, Xuetao Han, Yu Wang, Xiang Zhan, Zizhou Zhang, Ge Zhang, Mengting Zhang, Weijing Cai, Huandi Zhou, Xiaoying Xue","doi":"10.1177/15330338261453490","DOIUrl":"10.1177/15330338261453490","url":null,"abstract":"<p><p>IntroductionGlioma is the most common primary malignant tumor of the central nervous system and remains associated with poor prognosis and limited effective biomarkers. Ribonucleotide reductase M2 (RRM2), a key enzyme involved in DNA synthesis, is frequently upregulated in multiple cancers; however, its pan-cancer characteristics and clinical significance in glioma remain incompletely defined.MethodsThis retrospective study integrated data from The Cancer Genome Atlas (TCGA), Therapeutically Applicable Research to Generate Effective Treatments (TARGET), and Genotype-Tissue Expression (GTEx) to characterize RRM2 expression patterns and prognostic relevance across 34 solid tumor types. Glioma (GBMLGG) was further analyzed to assess associations between RRM2 expression and Mutant-Allele Tumor Heterogeneity (MATH), stemness indices, clinicopathological features, and survival outcomes. An RRM2-based prognostic nomogram was constructed and externally validated. Differential expression analysis combined with Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Set Enrichment Analysis (GSEA) was performed to explore RRM2-associated biological pathways.ResultsRRM2 was significantly upregulated in 33 of 34 cancer types, with the strongest prognostic effect observed in GBMLGG. In glioma, RRM2 expression was markedly higher than in normal brain tissue (P < 0.001) and showed high diagnostic accuracy (AUC = 0.967). Elevated RRM2 expression was associated with advanced age, higher WHO grade, and Isocitrate Dehydrogenase (IDH) wild-type status, and predicted significantly poorer overall survival, disease-specific survival, and progression-free interval (all P < 0.001). A nomogram incorporating RRM2 expression, age, WHO grade, and IDH status demonstrated robust predictive performance for 1-, 3-, and 5-year survival. RRM2 expression was positively correlated with tumor stemness and negatively correlated with intratumoral heterogeneity, and was associated with enrichment of cell cycle and immune-related pathways.ConclusionRRM2 is markedly overexpressed in glioma and is strongly associated with tumor aggressiveness and poor prognosis. These findings support the potential value of RRM2 as a prognostic biomarker in glioma and suggest that it is associated with stemness-related and cell cycle-related biological features. Further studies are needed to clarify its mechanistic and therapeutic relevance.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261453490"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13180168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147960285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CBCT-based Online Adaptive Radiotherapy for Prostate Cancer: Dosimetrical Aspects and Comparison to Non-Adaptive Conventional IGRT.","authors":"Niklas Christian Scheele, Jann Fischer, Lovis Hampe, Tim Niemeier, Jessica Moldauer, Daniela Schmitt, Manuel Guhlich, Martin Leu, Leif Hendrik Dröge, Arne Strauß, Stefan Rieken, Laura Anna Fischer, Rami Ateyah El Shafie","doi":"10.1177/15330338251405772","DOIUrl":"10.1177/15330338251405772","url":null,"abstract":"<p><p>IntroductionDaily anatomical variations in prostate cancer radiotherapy, particularly due to pelvic organ motion and filling, can compromise target coverage and increase exposure to organs at risk (OARs). Conventional image-guided radiotherapy (IGRT) uses fixed safety margins and daily couch corrections to account for these variations, potentially leading to overtreatment of healthy tissue or insufficient tumor coverage. Online adaptive radiotherapy (oART), based on cone-beam computed tomography (CBCT), enables daily plan adaptation to the patient's anatomy, offering improved precision, enhanced target coverage, and better OAR sparing. This retrospective study compares oART to conventional IGRT in prostate cancer treatment.MethodsA total of 153 treatment fractions from six consecutive prostate cancer patients treated with oART on a Varian Ethos system were analyzed. For each fraction, three plans were evaluated: the scheduled plan (initial plan recalculated on daily CBCT), the adapted plan (reoptimized based on daily anatomy), and the verification plan (applied dose recalculated on a post-adaptation CBCT). Dose-volume metrics for target volumes and OARs were assessed, and clinical acceptability was evaluated. Interfractional prostate volume changes and treatment times were examined.ResultsCTV D_98% improved significantly with adaptation (median 97.85% to 98.55%; p < 0.01) and further increased in the verification plan (98.8%; p < 0.01), alongside reduced interquartile ranges. PTV D_98% rose from 90.1% to 97.1% with adaptation and to 96.9% after verification (p < 0.01). Bowel and bladder doses showed dosimetrical advantage. Clinically acceptable plans increased from 24.8% (scheduled) to 98% (adapted) and 85.6% (verification). Scheduled plans were not used clinically. Median prostate volume remained stable despite inter-individual variation. oART required about twice the treatment time of IGRT.ConclusionAlthough more time-consuming, oART improved target dose coverage and optimized OAR sparing, while simultaneously reducing dose variability for both the target and some OARs compared to IGRT. The plan acceptability improved significantly.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338251405772"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12796137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145960219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline PET/CT Radiomics and Clinical Indicators for Pretreatment Response Prediction in Unresectable Hepatocellular Carcinoma: Model Development and Internal Validation.","authors":"Yiwen Cheng, Cailong Chen, Yanyan Tang, Yanqing Xu, Juanzhen Huang, Qu Mo, Fuqi Xu, Dingluan Lin","doi":"10.1177/15330338261495839","DOIUrl":"https://doi.org/10.1177/15330338261495839","url":null,"abstract":"<p><p>IntroductionPretreatment prediction of benefit from targeted therapy plus immunotherapy remains uncertain in unresectable hepatocellular carcinoma (HCC). We developed and internally validated a model integrating baseline 18F-FDG PET/CT radiomics with clinical indicators.MethodsThis single-center retrospective study included 325 patients, comprising a development cohort (n = 182) and an internal validation cohort (n = 143). Clinical/PET, radiomics, and fusion logistic models were developed to predict 12-week objective response assessed according to the modified Response Evaluation Criteria in Solid Tumors. Development-derived preprocessing parameters, coefficients, and cutoffs were applied unchanged to validation. Discrimination was assessed using AUCs with bootstrap 95% confidence intervals and paired patient-level bootstrap comparisons; calibration was assessed using the Brier score, calibration intercept, and calibration slope.ResultsIn the 143-patient internal validation cohort, the clinical, radiomics, and fusion models had AUCs of 0.69 (0.60-0.77), 0.75 (0.67-0.83), and 0.84 (0.78-0.90), respectively. The paired AUC difference was 0.16 (95% CI, 0.05 to 0.26; P = 0.002) versus the clinical model and 0.09 (-0.001 to 0.19; P = 0.053) versus the radiomics model. The fusion-model Brier score was 0.16, calibration intercept was -0.02, and calibration slope was 0.83.ConclusionThe fusion model integrating clinical and radiomics features demonstrated favorable discrimination and calibration for predicting 12-week objective response in patients with HCC. It improved predictive performance compared with the clinical model alone and may provide a noninvasive tool for pretreatment response assessment. Prospective multicenter studies are warranted to evaluate its generalizability and clinical utility.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261495839"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiparametric MRI-Derived Habitat Radiomics in Subregional Analysis for Predicting Axillary Lymph Node Metastatic Burden in Breast Cancer.","authors":"Yaoqi Han, Fei Gao, Aimei Ouyang, Jing Wang, Chunling Zhang, Guoyue Chen, Xue Bing, Zhen Gao","doi":"10.1177/15330338261416806","DOIUrl":"10.1177/15330338261416806","url":null,"abstract":"<p><p>IntroductionAxillary nodal burden reflects the biological aggressiveness and prognostic behavior of breast cancer. This study aimed to develop a subregional habitat radiomics model based on multiparametric magnetic resonance imaging (MRI) and to evaluate its performance in predicting high axillary nodal burden in patients with breast cancer.MethodsIn this retrospective study, a total of 221 patients who underwent axillary lymph node dissection were categorized as having limited (0-2 metastatic nodes) or high (≥3 metastatic nodes) nodal burden based on pathological findings. Morphological MRI features were visually evaluated by experienced radiologists. A clinical model was established using univariate and multivariate logistic regression analyses. Conventional radiomics (C-radiomics) and habitat radiomics features were extracted from the whole tumor and its subregions, respectively, based on multiparametric MRI. The clinical, C-radiomics, and habitat radiomics models were then integrated into a comprehensive nomogram for quantitative prediction of axillary nodal burden.ResultsIn predicting axillary nodal burden, the habitat radiomics model outperformed both the C-radiomics and clinical models, achieving areas under the curve (AUCs) of 0.791 (0.712-0.870) and 0.798 (0.686-0.911) in the training and validation cohorts, respectively. The C-radiomics model achieved AUCs of 0.733 (0.631-0.836) and 0.738 (0.612-0.865), while the clinical model achieved AUCs of 0.753 (0.663-0.843) and 0.733 (0.596-0.870). The combined nomogram demonstrated the highest diagnostic performance, with AUCs of 0.895 (0.839-0.951) and 0.885 (0.802-0.969) in the training and validation cohorts, respectively.ConclusionsThe integrated nomogram combining clinical, C-radiomics, and habitat radiomics models demonstrated strong predictive efficacy for preoperative assessment of axillary nodal burden in breast cancer. Future multicenter prospective studies are warranted to validate these results and refine the model's clinical applicability.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261416806"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12816545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}